Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria.
We investigated two independent cohorts of patients with advanced solid tumours treated in phase I trials with (i) programmed cell death 1 (PD-1)/PDL-1 antibodies in monotherapy or combination; and (ii) targeted agents (TAs) in unapproved indications. A RECIST 1.1 (RECIST) -based definition of hyperprogression was developed. The primary endpoint was the assessment of the rate of HPD in patients treated with ICIs or TAs using both criteria (RECIST and TGR) and the impact on overall survival (OS) in patients who achieved PD as best response. RESULTS Among 270 evaluable patients treated with PD-1/PD-L1 inhibitors. 29 PD-1/PD-L1 treated patients (10.7%) had HPD by RECIST definition. This group had a significantly lower OS (median of 5.23 months, 95% CI 3.97-6.45) when compared with non-HPD progressors group (median 7.33 months, 95% CI 4.53-10.12; HR = 1.73, 95% CI 1.05-2.85; p = 0.04). In a subset of 221 evaluable patients, 14 (6.3%) were categorized as HPD using TGR criteria, differences in mOS between this group (mOS 4.2 months; 95% IC 2.07-6.33) and non-HPD progressors (n=44) by TGR criteria (mOS 6.27 months; 95% CI 3.88-8.67) were not statistically significant (HR 1.4, 95% IC 0.70-2.77; p = 0.346). Among 239 evaluable patients treated with TAs, 26 (10.9%) were classified as having HPD by RECIST and 14 using TGR criteria in a subset of patients. No differences in OS were observed between HPD and non-HPD progressors treated with TAs. CONCLUSIONS HPD measured by TGR or by RECIST was observed in both cohorts of patients, however in our series there was an impact on survival only in the ICI cohort when evaluated by RECIST. We propose a new way to capture HPD using RECIST criteria that is intuitive and easy-to use in daily clinical practice.